Camp4 Therapeutics Files S-1 for Public Offering

TL;DR

Camp4 Therapeutics is going public, filing its S-1 today.

AI Summary

Camp4 Therapeutics Corp. filed an S-1 registration statement on September 20, 2024, to offer its securities. The company, incorporated in Delaware, is based in Cambridge, Massachusetts, and operates in the pharmaceutical preparations sector. Josh Mandel-Brehm is listed as the Chief Executive Officer.

Why It Matters

This S-1 filing indicates Camp4 Therapeutics is preparing to become a publicly traded company, which could provide it with capital for further research and development in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — As an S-1 filing, it represents a company in the process of going public, which inherently carries risks associated with market reception and early-stage biotechnology operations.

Key Numbers

• 333-282241 — SEC File Number (Identifies the specific registration filing with the SEC.)
• 0001736730 — Central Index Key (CIK) (Unique identifier for Camp4 Therapeutics Corp. in the SEC EDGAR system.)

Key Players & Entities

• Camp4 Therapeutics Corp. (company) — Registrant
• September 20, 2024 (date) — Filing Date
• Delaware (jurisdiction) — State of Incorporation
• Cambridge, Massachusetts (location) — Principal Business Address
• Josh Mandel-Brehm (person) — Chief Executive Officer
• 2834 (industry_code) — Pharmaceutical Preparations SIC Code

FAQ

Filing Documents

• tm2415452-8_s1.htm (S-1) — 3846KB
• tm2415452d9_ex4-1.htm (EX-4.1) — 245KB
• tm2415452d9_ex4-2.htm (EX-4.2) — 80KB
• tm2415452d9_ex10-1.htm (EX-10.1) — 202KB
• tm2415452d9_ex10-2.htm (EX-10.2) — 39KB
• tm2415452d9_ex10-3.htm (EX-10.3) — 58KB
• tm2415452d9_ex10-4.htm (EX-10.4) — 188KB
• tm2415452d9_ex10-14.htm (EX-10.14) — 273KB
• tm2415452d9_ex10-15.htm (EX-10.15) — 476KB
• tm2415452d9_ex21-1.htm (EX-21.1) — 2KB
• tm2415452d9_23-1.htm (EX-23.1) — 2KB
• tm2415452d9_ex-filingfees.htm (EX-FILING FEES) — 19KB
• lg_camp4-4c.jpg (GRAPHIC) — 22KB
• ph_identify-4c.jpg (GRAPHIC) — 111KB
• fc_ourpipeline-4c.jpg (GRAPHIC) — 53KB
• ph_geneexpression-4c.jpg (GRAPHIC) — 78KB
• bc_functionaldisorder-4c.jpg (GRAPHIC) — 39KB
• ph_sodiumacetate-4c.jpg (GRAPHIC) — 58KB
• pc_ucdpatient-4c.jpg (GRAPHIC) — 50KB
• bc_concentration-4c.jpg (GRAPHIC) — 94KB
• lc_ureaproduction-4clr.jpg (GRAPHIC) — 55KB
• lc_ammonialevel-4c.jpg (GRAPHIC) — 95KB
• lc_ammoniaureagen-4clr.jpg (GRAPHIC) — 52KB
• bc_ucdmrna-4clr.jpg (GRAPHIC) — 51KB
• lc_ureagenesisauc-4c.jpg (GRAPHIC) — 46KB
• fc_clinicaltrialdesign-4c.jpg (GRAPHIC) — 64KB
• lc_syngap1brainsofmice-4clr.jpg (GRAPHIC) — 58KB
• lc_humanneurons-4c.jpg (GRAPHIC) — 55KB
• 0001104659-24-101618.txt ( ) — 6772KB

Risk factors

Risk factors 15 Special Note Regarding Forward-Looking Statements 82 Market and industry data 84

Use of proceeds

Use of proceeds 85 Dividend policy 87 Capitalization 88

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 93

Business

Business 111 Management 157 Executive and director compensation 167 Certain relationships and related party transactions 180 Principal stockholders 184

Description of capital stock

Description of capital stock 187 S hares Eligible for Future Sale 193 Certain Material U.S. Federal Income Tax Consequences to Non U.S. Holders 196

Underwriting

Underwriting 200 Legal matters 212 Experts 212 Where You Can Find More Information 212 Index to consolidated financial statements F-1 Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may provide you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained in this prospectus is accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside of the United States: neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. TABLE OF CONTENTS P ROSPECTUS SUMMARY This summary highlights, and is qualified in its entirety by, information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common stock. You should read this entire prospectus carefully, especially the sections titled "Risk factors," "Business," and "Management's discussion and analys

View Full Filing

View this S-1 filing on SEC EDGAR